Neurotoxin selection drives both clinical outcomes and practice economics. Onset speed shapes patient satisfaction and retreat intervals; duration affects revenue predictability; unit dosing determines per-treatment cost; and wholesale pricing influences margin. A practice owner must understand not just the clinical profile of each toxin, but the real-world acquisition economics—what you pay per unit, how that translates to per-treatment cost, and how each product fits your patient mix and cash-flow model. This guide compares the five FDA-cleared options on the metrics that matter to your bottom line.